text stringlengths 1 654k |
|---|
08-29-2013 |
View PostDarth_Clicker, on 25 June 2018 - 05:13 AM, said: |
Ignore the great Karl?!?!?!!? Oh...the travesty...:amazed:..the tragedy...:ohmy:..the horror....:angry:......:izmena:.......:teethhappy::harp: |
Only ignoring it for the sake of in-game crew vs. reality crew. |
Because the 8-bit Karl had only a lonely commander that had to do everything while the actual artillery piece had something like |
1 Commander |
2 Drivers |
18 Gunners/Loaders (Wikipedia is kinda ambiguous about the distribution of them) |
So if a vehicle has a wee bit more crew members than what the game mechanics currently allow WG has proven not to have the slightest qualms about reducing them to workable numbers. |
Darth_Clicker #20 Posted 25 June 2018 - 05:39 PM |
Lieutenant Сolonel |
• Player |
• 61403 battles |
• 3,436 |
• [4RCE] 4RCE |
• Member since: |
04-30-2013 |
View PostOrkbert, on 25 June 2018 - 04:36 PM, said: |
Only ignoring it for the sake of in-game crew vs. reality crew. |
Because the 8-bit Karl had only a lonely commander that had to do everything while the actual artillery piece had something like |
1 Commander |
2 Drivers |
18 Gunners/Loaders (Wikipedia is kinda ambiguous about the distribution of them) |
So if a vehicle has a wee bit more crew members than what the game mechanics currently allow WG has proven not to have the slightest qualms about reducing them to workable numbers. |
I understand. As long as you know that ignoring the great Karl SPG is akin to ignoring Elvis or The Beatles when talking about music. :B |
Edited by Darth_Clicker, 25 June 2018 - 05:39 PM. |
Also tagged with SPG, ART, Japan |
1 user(s) are reading this topic |
0 members, 0 guests, 0 anonymous users |
Working… |
ClinicalTrials.gov |
ClinicalTrials.gov Menu |
Trial record 4 of 543 for: RITA |
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1) (RITA-1) |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03740737 |
Recruitment Status : Active, not recruiting |
First Posted : November 14, 2018 |
Last Update Posted : September 17, 2019 |
Sponsor: |
Information provided by (Responsible Party): |
Ferring Pharmaceuticals |
Brief Summary: |
This trial investigates the effects of FE 999049 compared to placebo. |
Condition or disease Intervention/treatment Phase |
Infertility Drug: Follitropin delta Other: Placebo Phase 3 |
Layout table for study information |
Study Type : Interventional (Clinical Trial) |
Actual Enrollment : 642 participants |
Allocation: Randomized |
Intervention Model: Parallel Assignment |
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: Treatment |
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology |
Actual Study Start Date : October 26, 2018 |
Estimated Primary Completion Date : July 2021 |
Estimated Study Completion Date : July 2021 |
Resource links provided by the National Library of Medicine |
MedlinePlus related topics: Infertility |
Arm Intervention/treatment |
Experimental: Follitropin delta Drug: Follitropin delta |
Follitropin delta |
Other Names: |
• FE 999049 |
• Rekovelle |
Placebo Comparator: Placebo Other: Placebo |
Placebo |
Primary Outcome Measures : |
1. Cumulative ongoing pregnancy rate after the fresh cycle and cryopreserved cycles initiated within 12 months from the start of controlled ovarian stimulation (COS) [ Time Frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) ] |
Secondary Outcome Measures : |
1. Ongoing pregnancy rate in the fresh cycle and in the cryopreserved cycles [ Time Frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) ] |
2. Time from start of controlled ovarian stimulation (COS) to ongoing pregnancy across the fresh and cryopreserved cycles [ Time Frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) ] |
3. Ongoing implantation rate in the fresh cycle, the cryopreserved cycles and cumulatively [ Time Frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) ] |
4. Clinical pregnancy rate in the fresh cycle, the cryopreserved cycles and cumulatively [ Time Frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) ] |
5. Vital pregnancy rate in the fresh cycle, the cryopreserved cycles and cumulatively [ Time Frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) ] |
6. Implantation rate in the fresh cycle, the cryopreserved cycles and cumulatively [ Time Frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) ] |
7. Positive beta human chorionic gonadotropin (βhCG) rate in the fresh cycle, the cryopreserved cycles and cumulatively [ Time Frame: 10-14 days after transfer (up to approximately 14 months after start of stimulation) ] |
8. Proportion of participants in the fresh cycle with triggering of final follicular maturation (with human chorionic gonadotropin [hCG], with gonadotropin-releasing hormone [GnRH] agonist, and in total), cycle cancellation and transfer cancellation [ Time Frame: Up to 5 days after oocyte retrieval (up to 27 days aft... |
9. Number of follicles on stimulation day 5 [ Time Frame: On stimulation day 5 ] |
The total number of follicles and the number of follicles per size category will be reported |
10. Number of follicles at end-of-stimulation [ Time Frame: At end-of-stimulation (up to 20 stimulation days) ] |
The total number of follicles and the number of follicles per size category will be reported |
11. Number of oocytes retrieved [ Time Frame: On day of oocyte retrieval (up to 22 days after start of stimulation) ] |
12. Proportion of participants with <4, 4-7, 8-14, 15-19 and ≥20 oocytes retrieved [ Time Frame: On day of oocyte retrieval (up to 22 days after start of stimulation) ] |
13. Number of metaphase II oocytes [ Time Frame: On day of oocyte retrieval (up to 22 days after start of stimulation) ] |
14. Number of fertilized oocytes and fertilization rate [ Time Frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation) ] |
15. Number of blastocysts on day 5 after oocyte retrieval [ Time Frame: On day 5 after oocyte retrieval ] |
The number of blastocysts (total and good-quality) will be reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for... |
16. Endometrial thickness [ Time Frame: On stimulation day 5 and at end-of-stimulation (up to 20 stimulation days) ] |
Mean endometrial thickness will be reported |
17. Echogenicity pattern [ Time Frame: On stimulation day 5 and at end-of-stimulation (up to 20 stimulation days) ] |
The distribution of subjects with hypoechogenic, isoechogenic, or hyperechogenic endometrium will be reported |
18. Oocyte utilization rate [ Time Frame: On day of oocyte retrieval upto 12 months after start of controlled ovarian stimulation (COS) ] |
19. Oocyte efficiency index [ Time Frame: 8-9 weeks after transfer ] |
The oocyte efficiency index will be calculated based on the number of oocytes retrieved and the cumulative number of ongoing pregnancies |
20. Percentage of blastocysts surviving cryopreservation [ Time Frame: 0 hour (+0.5 hour) after thawing ] |
21. Percentage of blastocysts with re-expansion after cryopreservation [ Time Frame: 2.5 hour (±0.5 hour) after thawing ] |
22. Number of cryopreserved cycles initiated within 12 months from the start of controlled ovarian stimulation (COS), and number of cryopreserved cycles with blastocyst transfer [ Time Frame: Up to 12 months after start of stimulation ] |
The total number of cryopreserved cycles initiated and the number of cryopreserved cycles with blastocyst transfer will be reported |
23. Circulating concentrations of anti-mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, progesterone, inhibin A and inhibin B [ Time Frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation) ] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.